Abstracts tagged "Renal"

Abstract Number: 2694 • ACR Convergence 2025
Effect of Deucravacitinib Treatment on Renal Dysfunction–Associated Plasma Biomarkers From a Phase 2 Study in Patients With Systemic Lupus Erythematosus
Amit Saxena¹, Chun Wu², Brad Rovin³, Zahi Touma⁴, Xueer Chen⁵, Ilias Kouris⁶ and Jinqi Liu⁵, ¹Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ²Bristol Myers Squibb, Princeton, ³The Ohio State University, Columbus, OH, ⁴University of Toronto, Toronto, ON, Canada, ⁵Bristol Myers Squibb, Princeton, NJ, ⁶Bristol Myers Squibb, Boudry, Switzerland
Background/Purpose: Plasma biomarkers may play a role in understanding kidney health in patients with lupus, particularly in terms of early detection of lupus nephritis (LN),…
Abstract Number: 1530 • ACR Convergence 2025
The Renal Activity Index for Lupus Identifies and Predicts Complete Renal Remission or Absence of Kidney Involvement in Systemic Lupus Erythematosus
Guillermo Pons-Estel¹, Rosana Quintana¹, Romina Nieto¹, Hermine Brunner², Marina Scolnik³, Carmen Funes Soaje⁴, Paula Alba⁵, Veronica Saurit⁶, Mercedes Garcia⁷, GUILLERMO ARIEL BERBOTTO⁸, Inés Verónica Bellomio⁹, Mario Eduardo Kerzberg¹⁰, Graciela Gomez¹¹, Cecilia Pisoni¹², Vicente Juarez¹³, Ana Malvar¹⁴, Nélzio Silva¹⁵, ODIRLEI MONTICIELO¹⁶, Henrique Mariz¹⁷, Francinne Ribeiro¹⁸, Eduardo Borba¹⁹, Eloisa Bonfa¹⁹, Edgard Torres dos Reis-Neto²⁰, Iris Guerra Herrera²¹, Maria Loreto Massardo²², Gustavo Aroca-Martínez²³, Lorena Gómez Escorcia²⁴, Carlos Alberto Cañas²⁵, Gerardo Quintana-Lopez²⁶, Carlos Toro-Gutierrez²⁷, Mario Moreno Alvarez²⁸, MIGUEL SAAVEDRA²⁹, Margarita Portela Hernández³⁰, Hilda Fragoso-Loyo³¹, Luis H Silveira³², Ignacio García-De la Torre³³, Carlos Abud-Mendoza³⁴, Jorge Antonio Esquivel Valerio³⁵, Maria Isabel Acosta³⁶, Astrid Paats³⁷, Claudia S. Mora-Trujillo³⁸, Manuel Ugarte-Gil³⁹, Armando Calvo⁴⁰, Roberto Muñoz-Louis⁴¹, Martin Rebella⁴², Alvaro Danza⁴³, Federico Zazzetti⁴⁴, Ashley Orillion⁴⁵, Urbano Sbarigia⁴⁶ and Bernardo A. Pons-Estel⁴⁷, ¹Centro Regional de Enfermedades Autoinmunes y Reumáticas, GO-CREAR, Rosario, Argentina, Rosario, Argentina, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴Hospital Italiano de Córdoba, Córdoba, Argentina, Cordoba, Argentina, ⁵Hospital Córdoba y Sanatorio Allende, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina, Cordoba, Argentina, ⁶Hospital Privado Universitario de Cordoba, Córdoba, Argentina, Córdoba, Argentina, ⁷Hospital Interzonal General de Agudos “General San Martín” de la plata, La Plata, Argentina, ⁸Sanatorio Británico, Rosario, Argentina, ROSARIO, Argentina, ⁹Hospital Padilla, Tucumán, Argentina, San Miguel de Tucumán, Argentina, ¹⁰Hospital J.M Ramos Mejía, Buenos Aires, Argentina, CABA, Argentina, ¹¹Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹²CEMIC Centro de Educación Médica e Investigaciones Clínicas ‘‘Norberto Quirno”, Buenos Aires, Argentina, Ciudad Autonoma Buenos Aires, Argentina, ¹³Hospital Señor del Milagro Salta, Salta, Argentina, Salta, Argentina, ¹⁴Organización Médica de Investigación, Buenos Aires, Argentina, ¹⁵Hospital das Clinicas da Universidade Federal de Goias, Goias, Brazil, Goiânia, Brazil, ¹⁶Hospital de Clínicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, PORTO ALEGRE, Rio Grande do Sul, Brazil, ¹⁷Universidad Federal de Pernambuco, Pernambuco, Brazil, Pernambuco, Brazil, ¹⁸Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio De Janeiro, Rio de Janeiro, Brazil, ¹⁹Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²⁰Universidad Federal São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²¹Hospital del Salvador Santiago de Chile, Santiago, Chile, Santiago, Chile, ²²Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, Santiago, Chile, ²³Clínica de la Costa y Universidad Simón Bolívar, Barranquilla, Colombia, barranquilla, Colombia, ²⁴Clínica de la Costa y Universidad Simón Bolívar Barranquilla, Barranquilla, Colombia, Barranquilla, Colombia, ²⁵Fundación Valle del Lili, Universidad Icesi, Cali, Colombia, Cali, Colombia, ²⁶Facultad de Medicina, Universidad Nacional de Colombia; Hospital Universitario Fundación Santa Fe de Bogotá; Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, ²⁷Pontificia Universidad Javeriana de Cali, Cali, Colombia, Cali, Colombia, ²⁸Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador, Guayaquil, Ecuador, ²⁹Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico, MEXICO, Mexico, ³⁰Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico, Mexico City, Mexico, ³¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ³²Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, ³³Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, Guadalajara, Jalisco, Mexico, ³⁴Facultad de Medicina de la Universidad Autónoma de San Luis Potosí y Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, San Luis Potosí, Mexico, ³⁵Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., MONTERREY, Mexico, ³⁶Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asuncion, Paraguay, ³⁷Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asunción, Paraguay, ³⁸Hospital Nacional Edgardo Rebagliati Martins-EsSalud, Lima, Peru, Lima, Peru, ³⁹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ⁴⁰Hospital Nacional Cayetano Heredia Universidad Peruana Cayetano Heredia, Lima, Peru, Jesús María, Peru, ⁴¹Hospital Docente Padre Billini, Santo Domingo, Distrito Nacional, Dominican Republic, ⁴²Hospital de Clínicas, Facultad de Medicina, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, ⁴³Médica Uruguaya, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, Montevideo, Uruguay, ⁴⁴Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ⁴⁵Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ⁴⁶Johnson & Johnson, Beerse, Belgium, ⁴⁷Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina
Background/Purpose: Effective, non-invasive disease activity and treatment response assessments are needed for patients with systemic lupus erythematosus (SLE), especially if associated with kidney disease, i.e.…
Abstract Number: 2660 • ACR Convergence 2025
Understanding Gout in Women: Longitudinal Changes in Serum Urate Levels from Pre-menopause through Post-menopause
Shreya Billa¹, Sho Fukui¹, Misti Paudel², Takahiro Suzuki³, Ryosuke Imai⁴, Yuntae Kim⁵, Takehiro Nakai⁶, Hiromichi Tamaki⁶, mitsumasa kishimoto⁷, Hilde Ørbo¹, Sara Tedeschi¹, Hyon K. Choi⁸, Masato Okada⁹ and Daniel Solomon¹, ¹Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Department of Cardiovascular Medicine, St. Luke's International Hospital, Tokyo, Japan, ⁴Department of Pulmonary Medicine, St. Luke's International Hospital, Tokyo, Japan, ⁵Department of Gastroenterology, St. Luke's International Hospital, Tokyo, Japan, ⁶Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ⁷Kyorin University School of Medicine, Tokyo, Japan, ⁸MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Understanding longitudinal changes in serum urate (SU) allows for the development of evidence-based interventions for gout. Post-menopausal women, who are at risk of gout,…
Abstract Number: 1516 • ACR Convergence 2025
The Benefits of SGLT2i on GFR Slope and Proteinuria in SLE Depend on Subgroups of Diabetes Mellitus and Baseline eGFR
Jennifer Lee¹, Andrea Fava², Daniel Goldman³, Laurence Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) affects over 50% of SLE patients. Twenty percent of LN patients develop end-stage renal disease (ESRD) within 10 years. The 2021…
Abstract Number: 2640 • ACR Convergence 2025
Effectiveness of Biological and Target-Synthetic Treatment in Patients with Rheumatoid Arthritis and Kidney Dysfunction: A Large Prospective Registry Study
Sho Fukui¹, Hilde Ørbo², Sara Tedeschi¹, Hongshu Guan³, Leslie Harrold⁴, Heather Litman⁵ and Daniel Solomon¹, ¹Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ²Diakonhjemmet Hospital, Oslo, Norway, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, ⁴CorEvitas, Northborough, MA, ⁵Corrona, LLC, Waltham, MA
Background/Purpose: Kidney dysfunction is common in patients with rheumatoid arthritis (RA). However, there has been limited and conflicting evidence on the effectiveness of biologic and…
Abstract Number: 1147 • ACR Convergence 2025
Renal Manifestations in VEXAS Syndrome: A Systematic Review of Clinical Features, Pathology, and Outcomes
Akhila Arya Perumangote Vasudevan¹, Vishnu Mulavini², Rasiya Hashim³, Madhumitha Rondla⁴ and Dileep C Unnikrishnan⁵, ¹Yale University/Bridgeport Hospital, Stratford, CT, ²Calicut Medical College, Stratford, ³Franciscan Health Olympia & Chicago Heights, [email protected], IL, ⁴Texas tech university health sciences center, El paso, El Paso, TX, ⁵Bridgeport Hospital, Stratford, CT
Background/Purpose: VEXAS syndrome is a recently described, adult-onset autoinflammatory disease caused by somatic mutations in the UBA1 gene, typically affecting hematopoietic stem cells. Renal involvement…
Abstract Number: 2453 • ACR Convergence 2025
Belimumab Is Associated with Lower Risk of Progression to LN Compared with Standard of Care in Patients with SLE
Maral DerSarkissian¹, Yan Chen¹, Ariel Chao¹, Shumin Rui¹, Bronwyn Moore², Karen Worley³, Daniel Moldaver⁴, Jeffrey J. Ellis³ and Aarat M Patel⁵, ¹Analysis Group, Los Angeles, CA, ²Analysis Group, Montreal, QC, Canada, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA, ⁴GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, ⁵GSK, US Medical Affairs, Durham, NC
Background/Purpose: LN develops in ~40% of patients with SLE and is associated with increased risk of morbidity, including end-stage kidney disease, and mortality. Belimumab, a…
Abstract Number: 1143 • ACR Convergence 2025
Gout and Renal Failure-Related Mortality Trends in USA from 1999-2020: Analysis of CDC Wonder Database
Shiamak Cooper¹, Sanjana Thimmannagari², Ranjini Vengilote² and Asim Khanfar², ¹Rochester General Hospital, Irondequoit, NY, ²Rochester General Hospital, Rochester, NY
Background/Purpose: Gout is the most common form of inflammatory arthropathy, with a prevalence ranging from 0.1% to approximately 10% worldwide. Despite a well-established association between…
Abstract Number: 2439 • ACR Convergence 2025
Belimumab Versus Mycophenolate Mofetil in Lupus Nephritis: A Real-World Comparative Analysis
Ahmad Alomari¹, Nikita Shah², Miguel Rodriguez³ and Diala Alawneh⁴, ¹UCF- North Florida hospital, Gainesville, FL, ²UCF/HCA Florida North Florida Hospital, Gainesville, FL, ³SIMED Rheumatology, Gainesville, FL, ⁴University of Florida, Gainesville, FL
Background/Purpose: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), often leading to chronic kidney disease (CKD) and end-stage renal disease (ESRD).…
Abstract Number: 0908 • ACR Convergence 2025
E-602 (Efgitasialase alfa) Enhances Memory B Cell Depletion and Reduces Profibrotic Macrophages via Desialylation in Autoimmune Disease
Hrishikesh Mehta¹, Vijayashree Mysore¹, Chih-Hsing Chou¹, Lizhi Cao¹, Rui Liu², Tianrui Fan², Jijun Yuan², James Broderick¹ and Li Peng¹, ¹Palleon Pharmaceuticals, Waltham, MA, ²Shanghai Henlius Biotech, Shanghai, China (People's Republic)
Background/Purpose: Abnormal cell surface glycosylation has been observed in various autoimmune diseases, including systemic lupus erythematosus (SLE) and membranous nephropathy. Among these glycan modifications, sialoglycans…
Abstract Number: 2192 • ACR Convergence 2025
Survey of Healthcare Providers’ Knowledge and Attitudes Toward the Management of Uncontrolled Gout
Shilpa Sharan¹, Clare Sonntag², Beth Miller¹, Kaitlyn Mayer¹ and Nissreen Elfadawy³, ¹The HWP Group, Upper Saddle River, NJ, ²The HWP Group, Upper Saddle River, ³University Hospitals, Geauga Medical Center, Chardon, OH
Background/Purpose: Although uncontrolled gout (UG) is an inflammatory arthritis triggered by crystallization of monosodium urate within joints following hyperuricemia, increasing evidence supports its classification as…
Abstract Number: 0682 • ACR Convergence 2025
Predictors of Severe Outcomes in Scleroderma Renal Crisis: Updated Results from a Single Center Study
Alex Luta¹, Saloni Mitchell² and Virginia Steen³, ¹Hospital for Special Surgery, New York, NY, ²Mount Sinai West and Morningside, New York, NY, ³Georgetown University School of Medicine, Washington, DC
Background/Purpose: Scleroderma Renal Crisis (SRC) is a severe manifestation of Systemic Sclerosis (SSc) associated with elevated morbidity and mortality. We aimed to address the challenges…
Abstract Number: 2043 • ACR Convergence 2025
Renal Outcomes of Long-term Canakinumab in Patients with Adult Familial Mediterranean Fever (FMF) and Biopsy-Confirmed AA Amyloidosis
Büşra Fırlatan Yazgan¹, Gözde Sevgi Kart bayram¹, Buğu Bulat¹, Levent Kılıç¹, Tolga Yildirim², Umut Kalyoncu¹, Şule Apraş Bilgen¹, Ali İhsan Ertenli¹, Seref Rahmi Yilmaz² and Omer Karadag³, ¹Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ²Division of Nephrology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ³Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey
Background/Purpose: Canakinumab, an interleukin-1β inhibitor, has demonstrated efficacy in treating colchicine-resistant/intolerant familial Mediterranean fever (FMF). This study aims to assess the efficacy and safety of…
Abstract Number: 0665 • ACR Convergence 2025
Infusion-Related Reactions (IRRs) and Hematologic Events Associated With Obinutuzumab in Lupus Nephritis: A Secondary Analysis of a Phase III Trial
Richard Furie¹, Teresa Baczkowska², Amit Saxena³, Imran Hassan⁴, Bongin Yoo⁵, Ben Lanza⁶, Himanshi Sehgal⁷, Frederic Boissard⁷, Jay Garg⁵, Thomas Schindler⁷, Elsa Martins⁷, William Pendergraft⁵ and Brad Rovin⁸, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Department of Transplantation Medicine, Nephrology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland, ³Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁴Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁵Genentech, Inc., South San Francisco, CA, ⁶Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸The Ohio State University, Columbus, OH
Background/Purpose: The REGENCY (NCT04221477) trial demonstrated superior efficacy of obinutuzumab and standard therapy (OBI+ST) over placebo and ST (PBO+ST) in patients (pts) with active lupus…
Abstract Number: 0729 • ACR Convergence 2024
Factors Associated with Pauci-immune Glomerulonephritis in Patients Undergoing Renal Biopsy with Positive ANCA Results
Jiyun Lee¹, Yeo-Jin Lee², Mi-Ra Cho³, Young-Eun Kim⁴, Soo Min Ahn⁴, Ji Seon Oh³, Yong-Gil Kim³, Chang-Keun Lee³, Bin Yoo³ and Seokchan Hong³, ¹University of Ulsan College of Medicine, Seoul, Republic of Korea, ²Asan medical center, Seoul, South Korea, ³Asan Medical Center, Seoul, Republic of Korea, ⁴Asan medical center, University of Ulsan College of Medicine, Seoul, Republic of Korea
Background/Purpose: Pauci-immune glomerulonephritis (GN) is a renal manifestation of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). When patients present with positive ANCA results and urinary abnormalities…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].